Repositioning Candidate Details
| Candidate ID: | R0635 |
| Source ID: | DB04874 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Picoplatin |
| Synonyms: | (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Picoplatin |
| Molecular Formula: | C6H10Cl2N2Pt |
| SMILES: | N.[Cl-].[Cl-].[Pt++].CC1=CC=CC=N1 |
| Structure: |
|
| DrugBank Description: | Picoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with solid tumors. It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription. |
| CAS Number: | 181630-15-9 |
| Molecular Weight: | 376.147 |
| DrugBank Indication: | For the treatment of patients with solid tumors. |
| DrugBank Pharmacology: | Picoplatin is a sterically hindered platinum (II) complex designed to deliver an extended spectrum of anti-cancer activity and overcome platinum resistance. |
| DrugBank MoA: | Picoplatin causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription. |
| Targets: | DNA |
| Inclusion Criteria: | Therapeutic strategy associated |
